Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?

CONCLUSIONS: patients who were progressive on P+ET could still benefit from a subsequent ET. In patients who experienced a good efficacy from prior ET, without visceral metastatic sites, HT seems the most suitable option, when compared to CT, also in terms of safety.PMID:34875670 | DOI:10.1159/000521252

Source: Oncology - December 7, 2021 Category: Cancer & Oncology Authors: Alessandra Fabi Mariangela Ciccarese Sinome Scagnoli Michelangelo Russillo Francesco Schettini Giuseppe Buono Vito Lorusso Katia Cannita Grazia Arpino Simonetta Stani Michela Palleschi Rosalba Rossello Giuseppina Sarobba Agnese Fabbri Marianna Giampaglia Source Type: research